S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:FWBI

First Wave BioPharma (FWBI) Stock Price, News & Analysis

$4.45
+0.50 (+12.66%)
(As of 03/28/2024 ET)
Today's Range
$3.85
$4.55
50-Day Range
$3.46
$9.24
52-Week Range
$2.75
$73.00
Volume
70,468 shs
Average Volume
307,640 shs
Market Capitalization
$3.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$118.00

First Wave BioPharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,551.7% Upside
$118.00 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of First Wave BioPharma in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$16,024 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($41.46) to ($5.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

FWBI stock logo

About First Wave BioPharma Stock (NASDAQ:FWBI)

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

FWBI Stock Price History

FWBI Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Why Is First Wave BioPharma (FWBI) Stock Up Today?
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
First Wave BioPharma price target set at $40 at Roth MKM
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
See More Headlines
Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2021
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FWBI
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$118.00
High Stock Price Target
$200.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+2,702.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-14,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$55.12 per share

Miscellaneous

Free Float
672,000
Market Cap
$2.86 million
Optionable
Not Optionable
Beta
1.29
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

FWBI Stock Analysis - Frequently Asked Questions

Should I buy or sell First Wave BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for First Wave BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FWBI shares.
View FWBI analyst ratings
or view top-rated stocks.

What is First Wave BioPharma's stock price target for 2024?

2 brokerages have issued 1 year target prices for First Wave BioPharma's stock. Their FWBI share price targets range from $36.00 to $200.00. On average, they anticipate the company's stock price to reach $118.00 in the next twelve months. This suggests a possible upside of 2,551.7% from the stock's current price.
View analysts price targets for FWBI
or view top-rated stocks among Wall Street analysts.

How have FWBI shares performed in 2024?

First Wave BioPharma's stock was trading at $4.20 at the beginning of the year. Since then, FWBI stock has increased by 6.0% and is now trading at $4.45.
View the best growth stocks for 2024 here
.

Are investors shorting First Wave BioPharma?

First Wave BioPharma saw a decrease in short interest in March. As of March 15th, there was short interest totaling 13,900 shares, a decrease of 54.1% from the February 29th total of 30,300 shares. Based on an average daily trading volume, of 741,400 shares, the short-interest ratio is currently 0.0 days. Approximately 0.9% of the company's shares are sold short.
View First Wave BioPharma's Short Interest
.

When is First Wave BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our FWBI earnings forecast
.

How were First Wave BioPharma's earnings last quarter?

First Wave BioPharma, Inc. (NASDAQ:FWBI) released its earnings results on Sunday, November, 14th. The company reported ($13,734.00) earnings per share for the quarter, missing the consensus estimate of ($3,318.00) by $10,416.00.

When did First Wave BioPharma's stock split?

Shares of First Wave BioPharma reverse split before market open on Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of First Wave BioPharma?

Shares of FWBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FWBI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners